Expression of putative targets of immunotherapy in acute myeloid leukemia and healthy tissues. - Wikidata - wikimedia - TriplyDB

Expression of putative targets of immunotherapy in acute myeloid leukemia and healthy tissues.

Expression of putative targets of immunotherapy in acute myeloid leukemia and healthy tissues.

http://www.wikidata.org/entity/Q42559107

about

Novel immunotherapeutic approaches for the treatment of acute leukemia (myeloid and lymphoblastic)Advancing the Minimal Residual Disease Concept in Acute Myeloid Leukemia The Impact of Normalization Methods on RNA-Seq Data Analysis.Current Approaches in the Treatment of Relapsed and Refractory Acute Myeloid Leukemia.A multigene array for measurable residual disease detection in AML patients undergoing SCT Cancer-testis antigen cyclin A1 is broadly expressed in ovarian cancer and is associated with prolonged time to tumor progression after platinum-based therapy.The antigenic landscape of multiple myeloma: mass spectrometry (re)defines targets for T-cell-based immunotherapy Systematic Prioritization of Druggable Mutations in ∼5000 Genomes Across 16 Cancer Types Using a Structural Genomics-based Approach Immunomodulatory Drugs: Immune Checkpoint Agents in Acute Leukemia.Adenosine Selectively Depletes Alloreactive T Cells to Prevent GVHD While Conserving Immunity to Viruses and Leukemia.Mapping the HLA ligandome landscape of acute myeloid leukemia: a targeted approach toward peptide-based immunotherapy.Immunological effects of hypomethylating agents.Leukemic progenitor cells are susceptible to targeting by stimulated cytotoxic T cells against immunogenic leukemia-associated antigens.

P2860

Q26770391-BBC90C55-C032-4F0B-B646-DB2D5A3B5104 Q28087291-A1C68172-B0C9-4748-BB3A-09FE51D1E780 Q30980468-9216ED9A-C275-4008-BC03-A405AB55236C Q35546759-CDE3B657-7561-4CF6-8FA8-13A388E468F2 Q35582360-8119DCCC-47BE-42A5-B75B-46C476EE2F31 Q35820674-BFC3A9D6-0B60-4543-BBEE-569B98475844 Q36169794-1F32A870-6E52-432D-A4E4-CF35788A1E7E Q36539506-8E178E50-8F38-481E-A639-D361488A1A3D Q38485334-888EE030-CBD0-42FB-8F6C-89491BA64439 Q40657274-B2263D79-EA35-49C7-A44F-D7C09C4DEF99 Q44976497-0A354202-5767-435D-9E9F-9F315602E3B2 Q48229616-0441372B-362A-4DCE-B06B-A9CF002B9DBA Q50447093-AB1BCC83-A159-4E11-93AF-A59A32095B3F

P2860

Expression of putative targets of immunotherapy in acute myeloid leukemia and healthy tissues.

http://www.wikidata.org/entity/Q42559107

description

2014 nî lūn-bûn

@nan

2014年の論文

@ja

2014年論文

@yue

2014年論文

@zh-hant

2014年論文

@zh-hk

2014年論文

@zh-mo

2014年論文

@zh-tw

2014年论文

@wuu

2014年论文

@zh

2014年论文

@zh-cn

name

Expression of putative targets ...... leukemia and healthy tissues.

@en

Expression of putative targets ...... leukemia and healthy tissues.

@nl

type

label

Expression of putative targets ...... leukemia and healthy tissues.

@en

Expression of putative targets ...... leukemia and healthy tissues.

@nl

prefLabel

Expression of putative targets ...... leukemia and healthy tissues.

@en

Expression of putative targets ...... leukemia and healthy tissues.

@nl

P1433

Q42559107-C7F14140-2D99-4828-9878-E85B22B241EE

P1476

Q42559107-36B22135-9052-477A-8F9C-0AF948BF97D3

P2093

Q42559107-09353E0F-1E53-411C-8FEB-7EFD882F9C41

Q42559107-0DE60DE2-D707-4AE4-B74D-D66FA36E4C1C

Q42559107-1A64D491-3FA5-4309-804D-83D2DD4A125D

Q42559107-4014AB69-6BBE-46BB-AF9C-43D4FE56B119

Q42559107-57E510EF-4C15-4E63-999D-2649E45EBC3B

Q42559107-69BE40B9-FFA4-44AC-8249-DCDB687407A9

Q42559107-717CABC6-5A83-4D2B-B5E4-EBEE6FB94E60

Q42559107-7357724F-E81E-451A-84D1-B3BDEF7FF7AD

Q42559107-89C25206-0E56-454F-9BE9-411DF461AA83

Q42559107-9D53BC4C-2C69-48F3-A3FD-96925B56E20A

P2860

Q42559107-0F3108DF-F315-4C08-8232-953C3C5D2F53

Q42559107-21BCA055-6837-40E5-A52D-42C2027313BB

Q42559107-235DBFE0-D207-41CD-8845-8A18BE902288

Q42559107-58074E43-9F23-4450-AE74-8C58B3C6A809

Q42559107-5A2BC107-9A24-4B89-BEB1-58F52D120F1C

Q42559107-677574F9-FAF0-47FE-AD07-CB4309EE58F4

Q42559107-8FDCEC0F-692C-4CEA-8029-37426441588F

Q42559107-93C04853-88E5-442F-9B91-8C07C44CAFCF

Q42559107-9C022911-F787-4413-9ADE-EF4BC65F8CE5

Q42559107-AEE4BCC2-D76F-45DB-B6CC-C5809C8AB130

P2888

Q42559107-033E77F6-9ED7-406B-AA0C-93219E770249

P304

Q42559107-45F9D85D-30D0-45C4-9722-11832A296A20

P31

Q42559107-B12EC941-9CA0-4FC7-9DBD-9CC29AFF63B8

P356

Q42559107-C21F1BF0-BE49-402D-9147-1A1039E4898D

P433

Q42559107-E84EF08F-8795-4388-8A1D-463810F19032

P478

Q42559107-2D4AB96F-15FE-40EC-B082-581388E20B44

P50

Q42559107-DE1F20D1-62F6-4C61-97EF-04D951B9EB9D

Q42559107-EB1B3967-7947-42AC-A086-097617BA72F7

P577

Q42559107-3AC36FFE-2164-42BE-961A-D0835E558620

P5875

Q42559107-CD322EE7-423E-4EEA-96E3-C742545B8832

P6179

Q42559107-63343096-74CB-4985-84C1-BB999B820653

P698

Q42559107-981B5277-D4BA-402F-AC9A-6203F9BD4C95

P921

Q42559107-9CEFF6F2-BAD0-4E07-AB41-861B6293C314

Q42559107-ECA256CD-22CA-4995-8D2A-0D1C6EE96C62

P932

Q42559107-E4A5485C-ED01-4D1B-AFAD-E16A1E36B7A8

P356

P1433

P1476

Expression of putative targets ...... d leukemia and healthy tissues

@en

P2093

A J Barrett

http://www.w3.org/2001/XMLSchema#string

A T Fathi

http://www.w3.org/2001/XMLSchema#string

B D Smith

http://www.w3.org/2001/XMLSchema#string

B N Savani

http://www.w3.org/2001/XMLSchema#string

G T Prince

http://www.w3.org/2001/XMLSchema#string

H I Levitsky

http://www.w3.org/2001/XMLSchema#string

H Sadrzadeh

http://www.w3.org/2001/XMLSchema#string

J W Fraser

http://www.w3.org/2001/XMLSchema#string

L Qin

http://www.w3.org/2001/XMLSchema#string

M Battiwalla

http://www.w3.org/2001/XMLSchema#string

P2860

Evaluation of current cancer immunotherapy: hemato-oncology

Analyzing real-time PCR data by the comparative C(T) method

Minimal residual disease in acute myeloid leukaemia

Cyclin-A1 represents a new immunogenic targetable antigen expressed in acute myeloid leukemia stem cells with characteristics of a cancer-testis antigen

FLT3-regulated antigens as targets for leukemia-reactive cytotoxic T lymphocytes.

Expression of tumor-associated antigens in acute myeloid leukemia: Implications for specific immunotherapeutic approaches.

Generation of multi-leukemia antigen-specific T cells to enhance the graft-versus-leukemia effect after allogeneic stem cell transplant

Induction of high-titer IgG antibodies against multiple leukemia-associated antigens in CML patients with clinical responses to K562/GVAX immunotherapy.

The prioritization of cancer antigens: a national cancer institute pilot project for the acceleration of translational research.

Immunotherapy for myeloid leukemias: current status and future directions.

P2888

P304

1167-1170

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1038/LEU.2014.14

http://www.w3.org/2001/XMLSchema#string

P433

5

http://www.w3.org/2001/XMLSchema#string

P478

28

http://www.w3.org/2001/XMLSchema#string

P50

Christopher S Hourigan

Stephen A. Strickland

P577

2014-01-10T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

259912332

http://www.w3.org/2001/XMLSchema#string

P6179

1017990758

http://www.w3.org/2001/XMLSchema#string

P698

24472813

http://www.w3.org/2001/XMLSchema#string

P921

P932

4013200

http://www.w3.org/2001/XMLSchema#string